The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
Apr. 03, 2018 08:48AM PST
Biotech InvestingresTORbio (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “We recently …
resTORbio (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2017.
As quoted in the press release:
“We recently completed our initial public offering, providing us the financial strength to pursue our goal of developing novel therapies for aging-related diseases. We are evaluating the potential of TORC1 inhibition to improve these diseases, beginning with our ongoing Phase 2b study evaluating RTB101 as an immunotherapy to reduce the incidence of respiratory tract infections in the elderly,” said Chen Schor, President and CEO of resTORbio. “In 2018, we look forward to reporting top-line data from this study in the second half of the year and to further developing RTB101, alone or in combination with everolimus, for the treatment of additional aging-related diseases.”
Latest News
Outlook Reports
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2337.93 | +0.46 | |
| Silver | 27.18 | +0.02 | |
| Copper | 4.59 | +0.05 | |
| Oil | 83.66 | +0.09 | |
| Heating Oil | 2.56 | 0.00 | |
| Natural Gas | 1.92 | +0.28 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.